MetaStat Spotlighted in Three Publications

Company’s Diagnostic Tests for Early Detection of Systemic Metastasis Spotlighted in Boston Magazine, Medical Device Daily and MedCity News

BOSTON--()--MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, was the subject of recent articles in Boston Magazine, Medical Device Daily and MedCity News.

“NewCo on the Go: MetaStat’s summer: new financing, spin-off, and positive study results”

The Boston Magazine article, “Boston Company To Introduce New Breast Cancer Diagnosis Tool,” focuses on the MetaSite Breast test’s potential to give doctors the ability to differentiate between metastatic and non-metastatic breast cancers, and eventually other types of cancer as well.

The Medical Device Daily article, “NewCo on the Go: MetaStat’s summer: new financing, spin-off, and positive study results,” describes the Company’s recent equity financing, reports the spinoff of its therapeutic assets and notes that positive results from a MetaSite Breast study were published in the Journal of the National Cancer Institute.

The MedCity News article, “Diagnostics company uses epigenetics principles to develop metastatic breast cancer test,” discusses how studies of the tumor microenvironment, along with an understanding of the function of the Mena protein, have allowed MetaStat to refine its diagnostic tests.

To read the Boston Magazine article, please visit the following link: www.bostonmagazine.com/health/blog/2014/10/21/metastat-breast-cancer-diagnosis/

To read the Medical Device Daily article, please visit the following link: www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=87394

To read the MedCity News article, please visit the following link: www.medcitynews.com/2014/09/diagnostics-company-uses-epigenetics-principles-develop-metastatic-breast-cancer-test/

About MetaStat, Inc.

MetaStat, Inc (MTST) is a molecular diagnostic company that develops and commercializes diagnostic tests for early and reliable prediction of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where systemic metastasis is responsible for approximately 90% of all deaths. The Company’s function-based diagnostic platform technology is based on the identification and understanding of the pivotal role of the mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors. Both the MetaSite Breast™ and MenaCalc™ assays are designed to accurately stratify patients based on their individual risk of metastasis and to provide physicians with clinically actionable information to better "customize" cancer treatment. MetaStat’s testing platform improves treatment planning decisions by positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy. The company is based in Boston.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.

Contacts

Media:
Dian Griesel Int’l. for MetaStat
Susan Forman, 212-825-3210
sforman@dgicomm.com
or
Investors:
MetaStat, Inc.
Daniel Schneiderman, 212-608-0827
Vice President
dan@metastat.com

Website

Release Summary

MetaStat's diagnostic technology for early prediction of systemic metastasis was featured in recent articles in Boston Magazine, Medical Device Daily and MedCity News.

MetaStat, Inc.